Compugen Reports Second Quarter 2026 Results
Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.
How this was made
The 30-second read
Why it matters
This release combines (1) Q2 2026 financial updates, (2) a reiterated clinical catalyst timeline for COM701 in platinum-sensitive ovarian cancer, and (3) partner program progress and a new overall survival readout for AstraZeneca’s rilvegostomig in biliary tract cancer.
Market read
Traders can use the reiterated COM701 interim-analysis timing (Q1 2027) and the stated cash runway into 2029 to frame biotech risk, while the new partner OS readout for rilvegostomig adds sentiment support for the broader checkpoint-pathway theme.
What to watch
Cash runway into 2029 is supportive, but the article does not quantify trial enrollment progress, event counts, or probability of success for COM701, which are key drivers of valuation for pre-registration-stage assets.
Background
Compugen is a clinical-stage cancer immunotherapy company with an AI/ML discovery platform (Unigen) and partnered programs including AstraZeneca’s rilvegostomig and Gilead’s GS-0321.
Ticker impact
Compugen reported Q2 2026 results and said its MAIA-ovarian COM701 interim analysis with median PFS is expected by Q1 2027.
Moderate positive bias, with volatility likely into the next clinical milestone and any follow-on partner updates.
The article provides fresh company-specific disclosures: Q2 financials, cash runway guidance, and a reiterated timing for the COM701 interim analysis. However, it does not include a new efficacy datapoint or regulatory decision that would typically drive a large immediate repricing.
Market effects
Reinforces investor attention on checkpoint-pathway innovation beyond PD-1/TIGIT (PVRIG) and on platform trial readouts as catalysts for oncology immunotherapy developers.
Limited direct regional spillover; primarily impacts US-listed biotech sentiment.
Partnered late-stage oncology programs (AstraZeneca) and IL-18 pathway interest (Gilead-linked GS-0321) may marginally influence global biotech risk sentiment.
Counterpoint
The reiterated Q1 2027 interim-analysis timing is not a new clinical result, so the market may already be pricing the catalyst; near-term reaction could fade if investors want hard efficacy updates sooner.
Key entities
- companyCompugen Ltd.
Subject of the earnings and corporate update, including COM701 MAIA-ovarian interim-analysis timing and Q2 2026 financial highlights.
- clinical_programCOM701
Compugen’s anti-PVRIG antibody in the MAIA-ovarian adaptive platform trial; interim median PFS expected by Q1 2027.
- partnerAstraZeneca
Partner presenting rilvegostomig data at ASCO 2026 and initiating an additional Phase 3 trial.
- clinical_programrilvegostomig
PD-1/TIGIT bispecific antibody; ASCO 2026 first overall survival readout reported with median OS 16.8 months.
- partnerGilead
Partner for GS-0321, with the Phase 1 dose-escalation trial progressing as planned.
